Review summary
Teaching objective: Limb-, sight- and heart-protecting primary care for a 70-year-old touring singer with type 2 diabetes, peripheral artery disease with claudication, diabetic macular edema, and coronary bypass surgery the year before: the comprehensive diabetic foot examination (inspection, 10-g monofilament, vibration, pulses) with the ankle- and toe-brachial indices, IWGDF risk grading and a high-risk foot program with podiatry and stage footwear; prompt vascular surgery evaluation, supervised exercise therapy, and a clear plan for revascularization if symptoms limit her life; a high-intensity statin with ezetimibe to an LDL below 55 mg/dL, aspirin with low-dose rivaroxaban, and glucose-lowering medicines with cardiovascular and kidney benefit (empagliflozin, then semaglutide) in place of a sulfonylurea; retinal care with anti-VEGF injections; kidney monitoring; hypoglycemia safety on tour (insulin timing across time zones, a continuous glucose monitor, glucagon, and a show-day plan); and the equity and access steps that make this care reach her, on the ADA Standards of Care 1987, the IWGDF 1984 guidelines, the 1985 ACC/AHA lower extremity PAD guideline, and the CMID diabetes monograph.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| April 25, 1917 | Born in Newport News, Virginia. | CLM-0001 |
| 1932 | Mother died; placed in an orphan asylum at 15. | CLM-0002 |
| 1934 | Won the Apollo Theater amateur contest. | CLM-0003 |
| 1958 | First Grammy Award. | CLM-0004 |
| 1970s | Health problems began; diabetes affected her eyes; cataract surgery, then touring more than 40 weeks a year. | CLM-0007, CLM-0008 |
| 1986 | Intensive care for heart trouble; quintuple-bypass heart surgery. | CLM-0009 |
| 1989 | Spoke of missing the road during her convalescence. | CLM-0013 |
| 1992 | National Medal of Freedom. | CLM-0005 |
| 1993 | Both legs amputated below the knee; created her charitable foundation. | CLM-0010, CLM-0011, CLM-0012 |
| June 15, 1996 | Died at home in Beverly Hills. | CLM-0014 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Ella Jane Fitzgerald was born on April 25, 1917, in Newport News, Virginia, to Temperance and William Fitzgerald. Most biographies gave 1918, but her birth certificate and school records show 1917. | confirmed | Ella Fitzgerald: career timeline supports 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports HISTMED Master Roster v3 context |
| D | In 1932 her mother died suddenly of a heart attack; orphaned at 15, she was placed in the Colored Orphan Asylum in Riverdale, New York. Family history from the cited source; age at death not given. |
confirmed | Ella Fitzgerald: career timeline supports |
| D | In 1934 she won an amateur contest at the Apollo Theater in Harlem, which brought her to the attention of the drummer and bandleader Chick Webb; she made her first recording with his band in 1935, and her 1938 swing version of the nursery rhyme "A-Tisket, A-Tasket" became her first hit. Her life as a performing singer anchors the modern social history. |
confirmed | 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports Ella Fitzgerald: career timeline supports |
| D | She won the Grammy Award for Best Jazz Individual Performance in 1958 for Ella Fitzgerald Sings the Duke Ellington Song Book, and received the Kennedy Center award for lifetime achievement in 1979. She was known as America's first lady of song. Achievement and identity, recorded as strengths. |
confirmed | Ella Fitzgerald: career timeline supports Ella Fitzgerald, 1917-1996: America's First Lady of Song supports |
| D | She was awarded the National Medal of Freedom in 1992. After the index date. |
confirmed | Ella Fitzgerald: career timeline supports |
| D | She began to have health problems during the 1970s; she had diabetes, which caused problems with her eyes. The anchor for the modern diabetic retinopathy. The type of diabetes and its treatment were not made public. |
confirmed | Ella Fitzgerald, 1917-1996: America's First Lady of Song supports |
| D | In the 1970s, after cataract surgery, she returned to touring more than 40 weeks a year. The anchor for the lens implants in the modern eye examination and for her touring life. |
confirmed | Scat lady supports |
| D | In 1986 she was admitted to intensive care for heart trouble and underwent quintuple-bypass heart surgery; the following year she was back onstage. The anchor for the modern coronary artery disease after bypass surgery the year before the index visit. |
confirmed | Ella Fitzgerald: career timeline supports Scat lady supports Ella Fitzgerald, 1917-1996: America's First Lady of Song supports |
| D | She had been suffering from diabetes and its circulatory system complications for many years before her death. The anchor for the modern peripheral artery disease. Reported at her death; no fetched source dates the start of the circulatory complications. |
confirmed | 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports |
| D | In 1993 both of her legs were amputated below the knees because of complications of diabetes. After the index date; history only. The modern episode does not stage or predict this outcome. |
confirmed | 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports Scat lady supports Ella Fitzgerald, 1917-1996: America's First Lady of Song supports |
| D | In 1993 she created and funded the Ella Fitzgerald Charitable Foundation, whose areas of interest include medical care and research with an emphasis on diabetes, vision problems, and heart disease. After the index date; recorded as a strength and as the conditions she chose to name. |
confirmed | The Ella Fitzgerald Charitable Foundation supports |
| D | In 1989, asked how she spent her convalescence, she said: "Staying home and being bored. I miss the road. I miss going overseas." Her own public words, after the index date; they show what performing and travel meant to her. |
confirmed | Scat lady supports |
| D | She died at home in Beverly Hills, California, on June 15, 1996, at 79. The exact cause of death was not released; one public timeline attributes it to complications of diabetes. History only; recorded in one sentence. |
confirmed | 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports Scat lady supports Ella Fitzgerald: career timeline supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | active | CLM-0007, CLM-0010 |
| S | Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | active | CLM-0007, CLM-0008 |
| S | Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | active | CLM-0009 |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 1987-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6% (high) Reference Below 5.7% is normal; her individualized goal is below 7.5% |
http://loinc.org · 4548-4 |
| S | 1987-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1987-05-11 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1987-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1987-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 67 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1987-05-11 | Glucose [Mass/volume] in Serum or Plasma | 168 mg/dL (high) Reference 70-99 mg/dL |
http://loinc.org · 2345-7 |
| S | 1987-05-11 | Albumin/Creatinine [Mass Ratio] in Urine | 18 mg/g Reference <=30 mg/g |
http://loinc.org · 9318-7 |
| S | 1987-05-11 | Cholesterol [Mass/volume] in Serum or Plasma | 164 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 1987-05-11 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 92 mg/dL Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL |
http://loinc.org · 13457-7 |
| S | 1987-05-11 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 1987-05-11 | Triglyceride [Mass/volume] in Serum or Plasma | 140 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 1987-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 U/L Reference 7-35 U/L |
http://loinc.org · 1742-6 |
| S | 1987-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 U/L Reference 10-35 U/L |
http://loinc.org · 1920-8 |
| S | 1987-05-11 | Hemoglobin [Mass/volume] in Blood | 12.4 g/dL Reference 11.6-15 g/dL |
http://loinc.org · 718-7 |
| S | 1987-05-11 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 386 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 1987-05-11 | Ankle-brachial index | 0.62 (low) Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal |
http://loinc.org · 77194-9 |
| S | 1987-05-11 | Ankle-brachial index | 0.74 (low) Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal |
http://loinc.org · 77194-9 |
| S | 1987-05-11 | Toe brachial index - right | 0.46 (low) Reference Above 0.70 normal |
http://loinc.org · 77618-7 |
| S | 1987-05-11 | Toe brachial index - left | 0.55 (low) Reference Above 0.70 normal |
http://loinc.org · 77617-9 |
| S | 1987-05-11 | Visual acuity best corrected Right eye by ETDRS eye chart | 64 (low) Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79876-9 |
| S | 1987-05-11 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79877-7 |
| S | 1987-06-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 1987-06-15 | Total score [Mini-Cog] | 5 | http://loinc.org · 72233-0 |
| S | 1987-06-15 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 1987-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.6% (high) Reference Below 5.7% is normal; her individualized goal is below 7.5% |
http://loinc.org · 4548-4 |
| S | 1987-08-10 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1987-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1987-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1987-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 64 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1987-08-10 | Cholesterol [Mass/volume] in Serum or Plasma | 128 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 1987-08-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 64 mg/dL Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL |
http://loinc.org · 13457-7 |
| S | 1987-08-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 1987-08-10 | Triglyceride [Mass/volume] in Serum or Plasma | 112 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 1987-08-10 | Visual acuity best corrected Right eye by ETDRS eye chart | 71 (low) Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79876-9 |
| S | 1987-08-10 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79877-7 |
| S | 1987-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.1% (high) Reference Below 5.7% is normal; her individualized goal is below 7.5% |
http://loinc.org · 4548-4 |
| S | 1987-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 1987-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.5 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 1987-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 mg/dL Reference 0.59-1.04 mg/dL |
http://loinc.org · 2160-0 |
| S | 1987-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 65 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 1987-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 114 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 1987-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 48 mg/dL Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL |
http://loinc.org · 13457-7 |
| S | 1987-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 47 mg/dL (low) Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 1987-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 96 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 1987-10-26 | Visual acuity best corrected Right eye by ETDRS eye chart | 75 (low) Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79876-9 |
| S | 1987-10-26 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 |
http://loinc.org · 79877-7 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 1987-05-11 | Body height | 165 cm | 8302-2 | S |
| 1987-05-11 | Body weight | 84 kg | 29463-7 | S |
| 1987-05-11 | Body mass index (BMI) [Ratio] | 30.9 kg/m2 | 39156-5 | S |
| 1987-05-11 | Systolic blood pressure | 126 mm[Hg] | 8480-6 | S |
| 1987-05-11 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1987-05-11 | Heart rate | 62 /min | 8867-4 | S |
| 1987-05-11 | Respiratory rate | 16 /min | 9279-1 | S |
| 1987-05-11 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1987-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1987-05-26 | Body height | 165 cm | 8302-2 | S |
| 1987-05-26 | Body weight | 83.8 kg | 29463-7 | S |
| 1987-05-26 | Body mass index (BMI) [Ratio] | 30.8 kg/m2 | 39156-5 | S |
| 1987-05-26 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 1987-05-26 | Diastolic blood pressure | 70 mm[Hg] | 8462-4 | S |
| 1987-05-26 | Heart rate | 60 /min | 8867-4 | S |
| 1987-05-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 1987-05-26 | Body temperature | 36.5 Cel | 8310-5 | S |
| 1987-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1987-08-10 | Body height | 165 cm | 8302-2 | S |
| 1987-08-10 | Body weight | 82.1 kg | 29463-7 | S |
| 1987-08-10 | Body mass index (BMI) [Ratio] | 30.2 kg/m2 | 39156-5 | S |
| 1987-08-10 | Systolic blood pressure | 122 mm[Hg] | 8480-6 | S |
| 1987-08-10 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1987-08-10 | Heart rate | 62 /min | 8867-4 | S |
| 1987-08-10 | Respiratory rate | 16 /min | 9279-1 | S |
| 1987-08-10 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1987-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
| 1987-10-26 | Body height | 165 cm | 8302-2 | S |
| 1987-10-26 | Body weight | 80.6 kg | 29463-7 | S |
| 1987-10-26 | Body mass index (BMI) [Ratio] | 29.6 kg/m2 | 39156-5 | S |
| 1987-10-26 | Systolic blood pressure | 120 mm[Hg] | 8480-6 | S |
| 1987-10-26 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1987-10-26 | Heart rate | 60 /min | 8867-4 | S |
| 1987-10-26 | Respiratory rate | 16 /min | 9279-1 | S |
| 1987-10-26 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1987-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 1987-06-15 | Body height | 165 cm | 8302-2 | S |
| 1987-06-15 | Body weight | 83.4 kg | 29463-7 | S |
| 1987-06-15 | Body mass index (BMI) [Ratio] | 30.6 kg/m2 | 39156-5 | S |
| 1987-06-15 | Systolic blood pressure | 124 mm[Hg] | 8480-6 | S |
| 1987-06-15 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 1987-06-15 | Heart rate | 60 /min | 8867-4 | S |
| 1987-06-15 | Respiratory rate | 16 /min | 9279-1 | S |
| 1987-06-15 | Body temperature | 36.6 Cel | 8310-5 | S |
| 1987-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Singer; back on stage since recovering from her heart surgery, touring in the United States and overseas, often two or three late shows a week with long travel days and meals at irregular times; performing is the center of her life
- S Lives in her own home; a road manager and her musicians travel with her; a long-time dresser helps her prepare for shows. She decides who is told about her health
- S Tobacco: does not smoke. Alcohol: rarely (AUDIT-C at the wellness visit). No other drugs
- S Activity: stands for long sets on stage in heeled shoes; walks little off stage because of calf pain
- S Access and equity: Medicare with a Part D plan and a supplemental plan; misses appointments when touring; reads standard print with difficulty because of her right eye. The clinic schedules around tour dates, uses video visits on the road, sends large-print instructions, checks drug costs before prescribing, and coordinates with clinics in tour cities
- S Supports and strengths: her music, her audiences, her band and road manager, and decades of experience of her own body on the road
Functional status
- S Independent in all activities of daily living; walks about one and a half blocks before calf pain stops her; uses a wheelchair in large airports; stands through 75-minute sets
Mental status
- S Alert, warm, and engaged; worried about her legs and her eyes and determined to keep performing
Allergies and medications
Allergies
- S No known allergy
Medications
- S Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals
- S Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals
- S Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime
- S Insulin glargine 100 units/mL pen, 24 units under the skin each morning
- S Atorvastatin 40 mg oral tablet, one tablet by mouth daily
- S Atorvastatin 80 mg oral tablet, one tablet by mouth daily
- S Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily
- S Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily
- S Empagliflozin 10 mg oral tablet, one tablet by mouth each morning
- S Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose
- S Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg
- S Semaglutide 0.25 mg under the skin once weekly for four weeks
- S Semaglutide 0.5 mg under the skin once weekly
- S Ezetimibe 10 mg oral tablet, one tablet by mouth daily
Procedures and immunizations
Procedures
- S Advance care planning conversation, about 18 minutes
- S Right-eye intravitreal anti-VEGF injection by the retina clinic (dose 1 of 3 monthly loading doses)
- S Podiatry: reduction of calluses under the second metatarsal heads, nail care, and fitting for protective and low-heeled stage shoes
- S Right-eye intravitreal anti-VEGF injection (dose 2 of 3)
- S Right-eye intravitreal anti-VEGF injection (dose 3 of 3)
- S Right-eye intravitreal anti-VEGF injection (first extended interval, six weeks)
- S Podiatry: reduction of calluses and nail care, three-month review
- S Right-eye intravitreal anti-VEGF injection (interval extended to eight weeks after this dose)
Immunizations
- S 1987-06-15: Pneumococcal conjugate vaccine (PCV20)
- S 1987-10-26: Influenza vaccine, high-dose, 1987-1988 season
- S 1987-10-26: Recombinant zoster vaccine, dose 1 of 2
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1970s: Diabetes affecting her eyes, with health problems beginning in the 1970s (CLM-0007)
- D 1970s: Cataract surgery, after which she returned to touring more than 40 weeks a year (CLM-0008)
- D 1986: Intensive care admission for heart trouble and quintuple-bypass heart surgery (CLM-0009)
Family history
- D mother: Died suddenly of a heart attack in 1932; age at death not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months | 1987-10-26 | completed | No level 2 or 3 lows since intake; time below 70 mg/dL under 1% |
| A1c below 7.5% by six months | 1987-10-26 | completed | A1c 7.1% |
| LDL cholesterol below 55 mg/dL by six months | 1987-10-26 | completed | LDL 48 mg/dL on atorvastatin 80 mg and ezetimibe |
| Walk at least four blocks without stopping by six months | 1987-10-26 | completed | Walks about five blocks before calf pain |
| No foot ulcer, and protective footwear on and off stage, through six months | 1987-10-26 | completed | No ulcer; low-heeled custom stage shoes and protective daily shoes |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color change | completed | GL-IWGDF-2023, GL-ADA-2026, GL-CMID-2026 |
| Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissue | completed | GL-ACC-PAD-2024, GL-IWGDF-PAD-2023 |
| Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explained | completed | GL-ADA-2026, GL-CMID-2026 |
| Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%) | completed | GL-ADA-2026, GL-CMID-2026 |
| Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHg | completed | GL-ADA-2026, GL-ACC-PAD-2024, GL-AHA-CCD-2023, GL-CMID-2026 |
| Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materials | completed | GL-ADA-2026, GL-CMID-2026 |
| Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformin | completed | GL-ADA-2026, GL-CMID-2026 |
| Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touring | completed | GL-ADA-2026, GL-ACC-PAD-2024 |
| Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for life | completed | GL-ACC-PAD-2024 |
| Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillers | completed | GL-ACC-PAD-2024, GL-ADA-2026 |
| Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six months | completed | GL-ACC-PAD-2024, GL-IWGDF-PAD-2023 |
| Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dL | completed | GL-ADA-2026, GL-STRIDE-2025, GL-CMID-2026 |
Planned encounters
- 1987-05-11 — New patient visit: diabetes with calf pain on walking, low glucose after late shows, eye and foot examinations, and cardiovascular risk (ENC-001)
- 1987-05-26 — Two-week review: glucose and hypoglycemia safety on the new plan, and vascular surgery consultation (ENC-002)
- 1987-06-15 — Subsequent annual wellness visit (ENC-005)
- 1987-08-10 — Three-month review: A1c, lipids, walking program, eye treatment, and foot care (ENC-003)
- 1987-10-26 — Five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up (ENC-004)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Annual Wellness Visit, Subsequent
- Progress note 04 — Focused Visit (Follow-up)
- Progress note 05 — Focused Visit (Care-plan review)
- Vascular Surgery referral
- Vascular Surgery consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Annual Wellness Visit, Subsequent (XML)
- Progress note 04 — Focused Visit (Follow-up) (XML)
- Progress note 05 — Focused Visit (Care-plan review) (XML)
- Vascular Surgery referral (XML)
- Vascular Surgery consultation (XML)
Sources
| ID | Source | Publisher | Type |
|---|---|---|---|
| SRC-0001 | 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style | The Spokesman-Review (wire reports) | other |
| SRC-0002 | Ella Fitzgerald: career timeline | American Masters, PBS (WNET) | biography |
| SRC-0003 | Scat lady | Newsweek | other |
| SRC-0004 | Ella Fitzgerald, 1917-1996: America's First Lady of Song | VOA Learning English (Voice of America) | government |
| SRC-0005 | The Ella Fitzgerald Charitable Foundation | The Ella Fitzgerald Charitable Foundation (official site) | primary |
| SRC-0008 | HISTMED Master Roster v3 | The Human Record project | other |
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the hypoglycemia plan (glipizide stopped, glargine reduced and moved to the morning), empagliflozin and semaglutide with peripheral artery disease and retinopathy, low-dose rivaroxaban with aspirin, the decision to defer revascularization during supervised exercise therapy, and the IWGDF risk grading. |
| provenance review | not_started | A 1996 wire obituary, the PBS American Masters timeline, a Newsweek obituary, VOA Learning English, and the official foundation page are logged. Every health claim is from these public reports; the type of diabetes and all modern findings are synthetic. |
| safe messaging review | not_started | Recent-death rule applies. The 1993 amputations and her death are recorded as history only, in plain sentences; the modern episode does not stage or predict them. No mental-health or substance claim is made. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.